ABSTRACT
AIM This study will describe the notion about survival analysis and the variability between diverse methods and test statistics used in analyzing survival data.
METHODS This study will be using the Veterans’ Administrative Lung Cancer dataset(R Dataset) of 137 patients having advanced inoperable Lung cancer, carried out by the US Veterans Administration. Out of 137 male patients, 69 patients received the Standard test while 68 patients received Chemotherapy test and 64 patients died in each treatment group while only 9 patients were alive (censored) at the end of the study. This dataset will be analyzed using the SPSS version to determine whether there is a statistically remarkable difference between the survival distributions of the cell types of Lung cancer using Life tables, and also between the Standard test and Chemotherapy test treatment groups using Kaplan Meier method. Various covariates were also analyzed to find out if they have any effect on the death of the male patients with advanced inoperable lung cancer using Cox-Regression.
RESULTS The Wilcoxon (Gehan) statistic from Life table method shows a p-value of 0.000 less than the 95% confidence level indicating that there is a statistical significance between the Lung cancer cell types. The three statistical tests of Kaplan-Meier method which include Log Rank (Mantel-Cox) test, Breslow (Generalized Wilcoxon) and Tarone Ware tests showed that the survival distribution between the two Lung cancer treatment groups are equal using an alpha level of 0.05.The Standard test and the Chemotherapy test drug treatment show the same effect on the survival time of the patients, no treatment is more beneficial than the other. Cox Regression result showed that Squamous cell type2(4), Adeno-carcinoma cell type (1), Small cell type (3) and karnofsky score are statistically significant while Large cell type2 (2), prior therapy, age, diagnosis time and the treatment group were found not significant.
CONCLUSION The treatment difference does not show any remarkable effect on the survival time of male patients with Lung Cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used for the study are available at http://lib.stat.cmu.edu/datasets/veteran